This is BrainsWay’s global website. The website includes information on clinical indications that were not cleared by the FDA and are considered investigational by the U.S. medical device regulations. BrainsWay treatment is FDA cleared for patients with MDD who failed to respond to one or more anti-depressants in the current episode.
is ushering in a new era of brain disorder treatment. Through ongoing investment in R&D and in research initiatives ranging from large-scale multicenter trials to personalized medicine studies, BrainsWay represents the next-generation of treatments for depression, OCD, and other brain disorders, achieving outcomes not thought possible with traditional medical solutions.
*See response and remission rates in the MDD and OCD treatment pages
Alzheimer’s disease is a major cause of severe cognitive decline in the aged.
Bipolar disorder, also known as manic-depressive illness
A brain stroke is the loss of brain function due to a disturbance in the blood supply to the brain.
Multiple Sclerosis (MSc) is an inflammatory demyelinating condition of the central nervous system
Parkinson’s disease is a degenerative disorder of the central nervous system
Anti-psychotic medications are often effective for the positive symptoms of schizophrenia
Autism is a complex developmental disability that typically appears during the first three years of life
Post-traumatic stress disorder (PTSD) is an extreme anxiety response to a life-threatening situation
Neuropathy is common in the diabetic population, affecting approximately 50% of patients with long-lasting diseases.
Tobacco smoking is the leading cause of preventable death in developed countries.
BrainsWay OCD – a noninvasive, innovative treatment – is transforming the treatment of OCD.
Major Depressive Disorder is a neuropsychiatric disorder that is expressed in emotional, physiological and behavioral effects.
OF POPULATION IS COVERED BY REIMBURSEMENT